SAN DIEGO, CA--(Marketwire - October 24, 2012) -
Naviscan, the global leader in high-resolution, organ-specific molecular imaging, announced it has entered into a sales representative agreement with Ledford Medical Electronics, Inc. to augment its USA direct sales staff in distributing its high-resolution organ-specific PET Scanner. The breast application of the scanner is commonly known as Positron Emission Mammography or PEM. Naviscan is expanding its distribution to meet the demand generated by its ability to be more precise at identifying the extent of benign and cancerous breast lesions and, therefore, reducing the number of unnecessary procedures, as well its significant clinical advantages in characterizing neoadjuvant chemotherapy response and monitoring for recurrent disease.
Naviscan manufactures the only commercially-available organ-specific PET imaging scanner with breast biopsy guidance. The scanner uses PET technology to produce tomographic images that allow physicians to visualize breast tumors with a 1.6 mm resolution, the width of a grain of rice.
Ledford Medical Electronics has proven experience in the Diagnostic Imaging industry where the company achieved $400M+ in annual product and service sales at different times for both GE and Philips Healthcare. As such, Ledford Medical Electronics will have an exclusive arrangement with Naviscan across the USA to market its organ-specific PET scanner, PEM-guided biopsy system, and related service contracts.
"Representing Naviscan is a great opportunity for Ledford Medical to be involved with a product and technology that will have such a meaningful impact on the future of Women's Health," Chuck Ledford commented.
"The recent volume of clinical publications and data has further proven PEM's clinical utility," said Paul J. Mirabella, CEO, Naviscan, Inc. "Expanding our USA distribution channel to meet demand is the next logical and exciting step."
About Naviscan, Inc.
Naviscan, founded in 1995, develops and markets compact, high-resolution PET scanners intended to provide organ-specific molecular imaging and guide radiological and surgical procedures. The Naviscan PET scanner is currently installed and available in breast and imaging centers throughout the world with global distribution in 34 countries. The Company is headquartered in San Diego, California and is the first to obtain FDA clearance and CE Mark for a high-resolution PET scanner designed to image small body parts and for breast biopsy image guidance.